CombiGene´s CEO provides an operational update
In connection with the release of Combigene’s year-end report for 2022, the gene therapy company’s CEO Jan Nilsson visited BioStock for a video interview. In addition to a review of the company’s ongoing projects, not least the recently initiated pain project with Danish Zyneyro, we get to know more about what is on the agenda for Combigene in 2023.
Watch the interview with CombiGene´s CEO Jan Nilsson below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
